Updating predictors of endoscopic recurrence after ileocolic resection for Crohn disease

Predicting Risk of Postoperative Disease Recurrence in Crohn’s Disease: Patients With Indolent Crohn’s Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery

“…The following variables were used to define risk based on a suspected high pretest probability of affecting disease severity or demonstration of a trend towards significance in univariate analysis: age, [14][15][16][17][18] gender, smoking, [14][15][16]18 disease behavior, 14,15 disease duration, 16,18 steroid use, 17,19 extent of resection, need for recurrent surgery, need for anti-TNFα therapy, need for alternative classes of biologic therapy, indication for change in biologic therapy, and most recent endoscopic activity. 16 Included variables that have also been associated with postoperative recurrence include smoking, [20][21][22][23] disease behavior, [24][25][26] shorter disease duration, [27][28][29] and prior resection. 6,30,31 All input variables were agreed upon by the research team.…”

Risk factors for endoscopic postoperative recurrence in patients with Crohn’s Disease: a protocol for systematic review and meta-analysis

“…2 studies [ 16 , 20 ] mentioned disease localization at ileocolic resection. Due to low heterogeneity (I 2 = 31.4%, P = 0.227), a random-effects model was utilized, and the result suggested that disease localization at ileocolic resection was a risk factor for ePOR, with statistical significance [OR = 2.68, 95% CI (1.38, 5.22), P = 0.004] (Fig.…”

“…9 studies [ 13 , 16 – 18 , 24 , 25 , 29 , 31 , 34 ] mentioned perianal disease. Due to low heterogeneity (I 2 = 46.5%, P = 0.060), a random-effects model was utilized, and the result demonstrated that perianal disease was a risk index for ePOR, with marked difference [OR = 1.47, 95% CI (1.07, 2.03), P = 0.017] (Fig.…”

“…Of the included 23 studies published from 2015 to 2023, 5 were case-control studies [13][14][15][16][17] and 18 were cohort studies [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]. Among them, 3 were from the Netherlands [19,20,33], 3 each from Italy [13,23,24] and China [15,28,31], 4 each from France [18,25,30,32] and the United States [21,26,27,29], and 1 each from Korea [14], Belgium [22], Portugal [16], Japan [34], Israel [35], and Brazil [17].…”

“…Of the included 23 studies published from 2015 to 2023, 5 were case-control studies [13][14][15][16][17] and 18 were cohort studies [18][19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35]. Among them, 3 were from the Netherlands [19,20,33], 3 each from Italy [13,23,24] and China [15,28,31], 4 each from France [18,25,30,32] and the United States [21,26,27,29], and 1 each from Korea [14], Belgium [22], Portugal [16], Japan [34], Israel [35], and Brazil [17]. The sample size of CD patients in each study ranged from 40 to 34, the number of patients with ePOR ranged from 23 to 169, and the age of the study population ranged from 24 to 49 years.…”